Find out what TRUXIMA® can do for you - Truxima® (rituximab) is the world's first monoclonal antibody (mAb) biosimilar in oncology ap-proved by the European Medicines Agency(EMA). Truxima® was approved by the EC for the same indications as the reference rituximab, based on data demonstrating comparability in terms of efficacy and safety. Truxima is indicated for the treatment of followings.

Herzuma®▼ is subject to additional monitoring

If you experience any side effects when taking Herzuma®▼ or any other medicine, talk to your doctor, pharmacist or nurse. This includes possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.


  •  

    Herzuma® is approved for the treatment of
    Early Breast Cancer.
    Learn More
  •  

    Herzuma® is approved for the treatment of
    Metastatic Breast Cancer (breast cancer that has spread beyond the original tumour).
    Learn More
  •  

    Herzuma® is approved for the treatment of
    Metastatic Gastric Cancer (gastric cancer that has spread beyond the original tumour).
    Learn More